4 Healthcare Stock Stories for Monday Investment Wellness

Novartis (NYSE:NVS): Current price $71.10

The Supreme Court of India has turned down Novartis AG’s request for patent protection for its Gleevec cancer treatment, which permits the country’s generic-drug makers to continue to sell copies of the drug at a lower price. This decision had been monitored by non-profit groups wanting to expand access to medicines as well as drugmakers worried about India’s position on intellectual property. On Monday, the court upheld regulatory rulings dating to 2006 that the drug was not sufficiently innovative to be worthy of a patent. Novartis contended that the molecule imatinib, on which Gleevec is based, required years of research and modification to make it an effective, safe leukemia treatment.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

NVS

Actavis (NASDAQ:ACT) Current price $92.63

The firm confirmed that it has filed an Abbreviated New Drug Application with the FDA, requesting approval to market Testosterone Gel, 1.62 percent. Actavis’s ANDA product is a generic version of AbbVie’s AndroGel 1.62 percent, which is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ACT

Laboratory Corporation of America Holdings (NYSE:LH): Current price $90.25

On Monday, the company said that LabCorp Clinical Trials had been chosen as a preferred provider for full-service global central laboratory services and biomarker testing by Bristol-Myers Squibb Company (NYSE:BMY). The five-year accord builds on a long-standing collaboration between the two firms, during which LabCorp’s global central lab, biomarker, and specialty testing capabilities have supported an array of Bristol-Myers Squibb early and late-stage clinical development programs.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

LH

Amarin Corporation (NASDAQ: AMRN): Current price $7.41

Shares are moving up Monday amid positive comments from Leerink Swann. Analyst Joseph Schwartz reported that IMS Health’s weekly publication of Vascepa prescription data are tracking well,  with the biggest TRx advance since its intro was recorded last week, with 1,504 recorded, while refills and new prescriptions are accelerating.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

AMRN

Don’t Miss: Will This Court Decision Be a Thorn in the Side of Novartis?